Zhifang Guo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Zhifang Guo has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Huikun Zhang
Department of Tumor Cell Biology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China
1 shared publication Jiaqi Jin
Laboratory of Cancer Cell Biology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin, China
1 shared publicationLang Chen
Laboratory of Cancer Cell Biology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin, China
1 shared publicationManzhi Gao
Laboratory of Cancer Cell Biology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin, China
1 shared publicationShaolu Zhang
Laboratory of Cancer Cell Biology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin, China
1 shared publicationSiqing Sun
Laboratory of Cancer Cell Biology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin, China
1 shared publication
Latest Publications
- Open Access
- 1 October 2026
- Published by Springer Nature in Cell Death & Disease
Acetylation-driven non-canonical transcriptional repressor ITSN1-S targets RASGRF1-GPX4 axis to induce breast cancer ferroptosis and anti-tumor immune remodeling
Breast cancer remains the most prevalent malignancy among women worldwide, yet robust molecular biomarkers are still lacking to advance precision oncology. Integrative analyses of our single-cell RNA sequencing (scRNA-seq) and mRNA microarray datasets identified endocytic protein, the short isoform of intersectin 1 (ITSN1-S), as a previously uncharacterized tumor suppressor, with its nuclear accumulation positively correlating with clinical prognosis in breast cancer. Mechanistically, CREB-binding protein (CBP)‑mediated acetylation facilitated nuclear translocation of ITSN1-S, enabling it to function as a non-canonical transcriptional repressor. Via directly binding to A/GCACACA core motif within RASGRF1 promoter, nuclear ITSN1-S transcriptionally repressed RASGRF1 . Functionally, this transcriptional repression inhibited breast cancer malignant progression and downregulated GPX4, thereby sensitizing breast cancer cells to cisplatin-induced ferroptosis. Further functional assays demonstrated that ITSN1-S-RASGRF1 axis-triggered tumor ferroptosis remodeled tumor immune microenvironment by driving tumor-associated macrophage (TAM) polarization towards anti-tumor M1 phenotype both in vitro and in vivo. Consistently, combined nuclear ITSN1-S and RASGRF1 expression status served as an independent prognostic factor for breast cancer patients. Collectively, this study advanced mechanistic insights into non-canonical transcriptional regulation driven by post-translationally modified endocytic proteins and offered promising prognostic biomarkers and druggable targets to reverse cisplatin resistance for breast cancer treatment.
- 1 October 2026
- Published by Springer Nature in Cell Death & Disease
Open AccessAcetylation-driven non-canonical transcriptional repressor ITSN1-S targets RASGRF1-GPX4 axis to induce breast cancer ferroptosis and anti-tumor immune remodeling
Breast cancer remains the most prevalent malignancy among women worldwide, yet robust molecular biomarkers are still lacking to advance precision oncology. Integrative analyses of our single-cell RNA sequencing (scRNA-seq) and mRNA microarray datasets identified endocytic protein, the short isoform of intersectin 1 (ITSN1-S), as a previously uncharacterized tumor suppressor, with its nuclear accumulation positively correlating with clinical prognosis in breast cancer. Mechanistically, CREB-binding protein (CBP)‑mediated acetylation facilitated nuclear translocation of ITSN1-S, enabling it to function as a non-canonical transcriptional repressor. Via directly binding to A/GCACACA core motif within RASGRF1 promoter, nuclear ITSN1-S transcriptionally repressed RASGRF1 . Functionally, this transcriptional repression inhibited breast cancer malignant progression and downregulated GPX4, thereby sensitizing breast cancer cells to cisplatin-induced ferroptosis. Further functional assays demonstrated that ITSN1-S-RASGRF1 axis-triggered tumor ferroptosis remodeled tumor immune microenvironment by driving tumor-associated macrophage (TAM) polarization towards anti-tumor M1 phenotype both in vitro and in vivo. Consistently, combined nuclear ITSN1-S and RASGRF1 expression status served as an independent prognostic factor for breast cancer patients. Collectively, this study advanced mechanistic insights into non-canonical transcriptional regulation driven by post-translationally modified endocytic proteins and offered promising prognostic biomarkers and druggable targets to reverse cisplatin resistance for breast cancer treatment.